Francesco Lo Savio

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
In phase II clinical trial, fingolimod at a dose of 5.0mg (ten times higher than the currently approved dose) induced dyspnoea and decreased forced expiratory flow in some patients, probably trought an airways constriction S1P4-mediated. In phase III trials, respiratory adverse events associated with fingolimod treatment as dyspnoea, cough, oropharingeal(More)
  • 1